MedPath

Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.

Not Applicable
Conditions
Severe Obesity
Morbid Obesity
Interventions
Procedure: Standard Roux-en-Y gastric bypass
Registration Number
NCT02409160
Lead Sponsor
Centro Universitário de Anapolis
Brief Summary

Obesity is a major public health problem in developed and developing countries, causing a range of respiratory and metabolic changes. There is a strong correlation between obesity and cardiorespiratory sleep disorders. The weight loss reduces the comorbidities and improves the quality of life, but clinical treatment it is not effective for a long period. In this context, currently bariatric surgery is an option for the real weight loss in the long term. Obstructive sleep apnea (OSA) is a common clinical condition observed in patients with obesity. The primary aim of this protocol are to assess the inflammatory profile of severe obese patients undergone to bariatric surgery, through systemic and adipose markers of inflammation. A secondary objective is study the impact of this surgery on sleep variables and quality of life. Investigators hypothesized that weight loss induced by bariatric surgery reduces systemic inflammatory profile, improve sleep quality and quality of life of subjects with severe obesity. Will participate in this study, patients with severe obesity (BMI \> 40 or 35 to 39.9 kg/m2 associated comorbidities), with indication of bariatric surgery, screened Bariatric Surgery Service of Santa Casa de São Paulo in São Paulo. Inclusion criteria are severely obese, bariatric surgery indication and agreement to participate in the study. Are excluded patients with BMI \> 55 kg/m2, clinical instability, mental instability or significant and unrealistic expectations of surgery. Patients will be assessed before and after bariatric surgery, 90, 180 and 360 days. The evaluation protocol will consist of clinical history, vital signs, neck and waist circumference, clinical analysis of blood inflammatory markers, lung function tests, maximal ventilatory pressures, full overnight standard polysomnography, excessive daytime sleepiness scale, cardiovascular risk, quality of life and personal satisfaction questionnaires.

Detailed Description

Obesity is a major public health problem in developed and developing countries, causing a range of respiratory and metabolic changes. There is a strong correlation between obesity and cardiorespiratory sleep disorders. The weight loss reduces the comorbidities and improves the quality of life, but clinical treatment it is not effective for a long period. In this context, currently bariatric surgery is an option for the real weight loss in the long term. Obstructive sleep apnea (OSA) is a common clinical condition observed in patients with obesity. Recent studies have found that more than 2/3 of obese patients also have OSA, and that these exhibit similar pathophysiological substrates for cardiovascular disease where increased blood pressure is a common consequence. This raises another discussion where obesity and OSA may have an additive effect on cardiovascular risk factors. Our main objective is to evaluate whether the systemic and adipose markers of inflammation alters after bariatric surgery through biochemical indexes in the visceral (omental, mesenteric) and subcutaneous adipose tissue depots and fasting blood samples, including the proinflammatory cytokines tumor necrosis factor α (TNFα), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 18 (IL-18), soluble TNF receptor-2 (sTNFR2), soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), monocyte chemoattractant protein 1 (MCP 1), high sensitivity C-reactive protein (hsCRP), adiponectin (AdipoQ) genes, vascular endothelial growth factor A (VEGF-A), nuclear factor Kappa B (NF-kB) and adipose-derived hormone leptin. Moreover, identify the possible association of systemic and adipose inflammation before bariatric surgery with the magnitude of surgery-induced weight loss and to assess pulmonary function through spirometry and, maximal ventilatory pressures through vacuometry; to determine whether surgical procedure induced decrease in body weight, BMI, abdominal circumference and, improve quality of life; to study sleep patterns through full standard polysomnography and quality of life in obese patients undergone to bariatric surgery and verify a possible correlation between weight loss and physiological variables. Will participate in this study, patients with severe obesity (BMI \> 40 or 35 to 39.9 kg/m2 associated comorbidities), with indication of bariatric surgery, screened Bariatric Surgery Service of Santa Casa de São Paulo in São Paulo. Inclusion criteria are severely obese, bariatric surgery indication and agreement to participate in the study. Are excluded patients with BMI \> 55 kg/m2, clinical instability, mental instability or significant and unrealistic expectations of surgery. Patients will be assessed before and after bariatric surgery, 90, 180 and 360 days. The evaluation protocol will consist of clinical history, vital signs, neck and waist circumference, clinical analysis of blood inflammatory markers, lung function tests, maximal ventilatory pressures, full overnight standard polysomnography, excessive daytime sleepiness scale, cardiovascular risk, quality of life and personal satisfaction questionnaires.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
17
Inclusion Criteria
  1. Patients eligible for the trial must comply with all of the following at randomization:
  2. male and female patients aged 18 to 65 years,
  3. grade III severe obesity (BMI ≥ 40 kg/m2) or ≥ 35 kg/m2 with comorbidities,
  4. awaiting bariatric surgery,
  5. with documented history of conventional weight loss attempts having proven unsuccessful over time,
  6. and if they are able to understand and agreement to participate in the study through a signed term of informed consent.
Exclusion Criteria
  1. Any medical condition rendering surgery too risky;
  2. BMI above 55 kg/m2;
  3. Unrealistic postoperative target weight and/or unrealistic expectations of surgical treatment;
  4. Pregnancy, lactation or planned pregnancy within two years of potential surgical treatment;
  5. Lack of safe access to abdominal cavity or gastrointestinal tract;
  6. Abusive alcohol use or drug use.
  7. Cancer
  8. Any cardiorespiratory condition opposite indicate the surgical procedure.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Bariatric SurgeryStandard Roux-en-Y gastric bypassStandard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
Primary Outcome Measures
NameTimeMethod
Change in systemic immune response after bariatric surgery.Baseline immune response to 180 days.

Systemic markers of inflammation through fasting blood samples biochemical indexes.

Change in systemic adipose inflammation response after bariatric surgery.Baseline adipose inflammation response to 180 days.

Systemic markers of inflammation through biochemical indexes in the visceral (omental, mesenteric) and subcutaneous adipose tissue depots.

Secondary Outcome Measures
NameTimeMethod
Alterations in sleep quality after bariatric surgery.180 days

Study sleep patterns through full standard polysomnography.

Changes in maximal ventilatory pressures after bariatric surgery.180 days

Assess maximal inspiratory and expiratory pressures through vacuometry.

Changes in pulmonary function after bariatric surgery.180 days

Assess pulmonary function through spirometry.

Changes in health related quality of life after bariatric surgery.180 days

Changes in quality of life through Short Form-36 and BAROS questionnaires.

Trial Locations

Locations (3)

Gastromed

🇧🇷

Anápolis, GO, Brazil

Centro Universitário de Anápolis - UniEVANGÉLICA

🇧🇷

Anápolis, GO, Brazil

Department of Surgery of Santa Casa of São Paulo Medical School, Gastric Surgery Division

🇧🇷

Sao Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath